Details of the Drug Combination

General Information of Drug Combination (ID: DCTRLUN)

Drug Combination Name
GSK2194069 Armodafinil
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs GSK2194069   DMZ2TD9 Armodafinil   DMGB035
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 16.8
Bliss Independence Score: 16.8
Loewe Additivity Score: 29.96
LHighest Single Agent (HSA) Score: 29.96

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of GSK2194069
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
GSK2194069 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fatty acid synthase (FASN) TT7AOUD FAS_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Armodafinil
Disease Entry ICD 11 Status REF
Malignant glioma 2A00.0 Approved [3]
Methamphetamine dependence 6C46.2 Approved [3]
Narcolepsy 7A20 Approved [3]
Pain MG30-MG3Z Approved [3]
Pediatric cancer 2A00-2F9Z Approved [4]
Postpoliomyelitis syndrome N.A. Approved [3]
Traumatic brain injury NA07.Z Approved [3]
Armodafinil Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Agonist [5]
------------------------------------------------------------------------------------
Armodafinil Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9.
3 Armodafinil FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
6 Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.
7 Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37.